Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
JUND
REST API REST API
Homo sapiens
JUND is differentially expressed in 350 experiments: 140 organism parts: liver, placenta, ... (138 more);, 219 disease states: normal, prostate carcinoma, ... (217 more);, 101 cell types 385 cell lines 67 compound treatments and 80 other conditions.
Synonyms AP-1
Orthologs Jund (Mus musculus)   jund (Danio rerio)   Jra (Drosophila melanogaster)   jund (Xenopus laevis)   Q9BGG7_CANFA (Canis familiaris)   (Compare orthologs)
InterPro Term bZIP_1, bZIP_2, Leuzip_Jun, JNK, TF_bZIP
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, sequence-specific DNA binding, protein dimerization activity, positive regulation of transcription from RNA polymerase II promoter, nucleus, chromatin, regulation of transcription from RNA polymerase II promoter, cellular response to calcium ion, osteoblast development, positive regulation of osteoblast differentiation, sequence-specific DNA binding transcription factor activity, transcription regulatory region DNA binding
UniProt Accession P17535
Search EB-eye ENSG00000130522
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
BT-474
2
E-GEOD-5823, E-GEOD-3529
MOLT4
2
E-MTAB-62, E-MTAB-37
PC3
2
E-GEOD-5258, E-MEXP-2034
SW620
2
E-MEXP-1014, E-MTAB-37
CORL88
1
E-MTAB-37
379 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (49 experiments)

Factor Value U/D Experiments
2
E-TABM-145, E-TABM-130
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
monocyte
2
3
E-MEXP-2019, E-GEOD-11755, E-GEOD-5099, E-MEXP-583, E-GEOD-8286 ... (5 experiments)
wild_type
1
E-GEOD-20193
CXCR5(-)ICOS(-/lo) CD4 T cell
1
E-MEXP-750
germ cell
1
E-MTAB-25
95 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (72 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-MEXP-2034, E-GEOD-7307, E-MTAB-62, E-GEOD-96, E-GEOD-5377 ... (5 experiments)
lung adenocarcinoma
1
3
E-MTAB-62, E-GEOD-2514, E-MEXP-231, E-MTAB-37
neuroblastoma
2
E-MTAB-37, E-MTAB-62
myxoid liposarcoma
2
E-GEOD-6481, E-MTAB-62
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
AIDS-KS, KSHV-
2
2
E-MTAB-62, E-MEXP-66
213 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-4668, E-TABM-782, E-GEOD-5824, ... (39 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-3284, E-GEOD-4006
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-TABM-868, E-GEOD-3720
placebo
2
E-MEXP-1335, E-MEXP-1327
17beta-estradiol
1
2
4
E-GEOD-2292, E-GEOD-4006, E-GEOD-4668
FLAP
1
E-GEOD-3202
61 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2359, E-GEOD-6236, E-MEXP-2283, ... (6 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-TABM-147, E-GEOD-21138, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-1045, E-MEXP-1437, E-GEOD-2466, E-GEOD-21750, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-GEOD-20540, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (40 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-6802, E-GEOD-512 ... (5 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (7 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, ... (6 experiments)

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2508, E-GEOD-19069, E-GEOD-2466, ... (6 experiments)

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-89, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.326 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM